共 243 条
[11]
Nishiwaki Y(2004)Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting Clin Cancer Res 10 6487-6501
[12]
Ohe Y(2005)Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations J Natl Cancer Inst 97 1185-1194
[13]
Yang JJ(2005)Establishment of a human non-small cell lung cancer cell line resistant to gefitinib Int J Cancer 116 36-44
[14]
Chewaskulyong B(2005)TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer J Clin Oncol 23 5892-5899
[15]
Jiang H(2004)Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial—INTACT 1 J Clin Oncol 22 777-784
[16]
Duffield EL(2004)Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial–INTACT 2 J Clin Oncol 22 785-794
[17]
Watkins CL(2007)Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial J Clin Oncol 25 1545-1552
[18]
Armour AA(2007)Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells Clin Cancer Res 13 3413-3422
[19]
Fukuoka M(2006)Rapamycin synergizes with the epidermal growth factor receptor inhibitor erlotinib in non-small-cell lung, pancreatic, colon, and breast tumors Mol Cancer Ther 5 2676-2684
[20]
Tortora G(2007)Rationale for a phase I trial of erlotinib and the mammalian target of rapamycin inhibitor everolimus (RAD001) for patients with relapsed non small cell lung cancer Clin Cancer Res 13 s4628-s4631